目的:适应超国家的欧洲牙周病联合会(EFP)种植体周围疾病的预防和治疗-英国医疗保健环境的EFPS3级临床实践指南,考虑到利益相关者和患者的广泛观点。
方法:这个英国版本,基于发表在“临床牙周学杂志”上的超国家EFP指南[1],是使用S3级方法开发的,将来自13项系统审查的正式证据评估与具有代表性的利益相关者团体的适度共识过程相结合,并解释健康平等,环境因素和临床疗效。它包括55种预防和治疗种植体周围疾病的临床建议,基于牙周和种植体周围疾病和状况的分类[2]。
方法:UK版本是使用称为GRADEADOLOPMENT框架的正式过程根据源指南开发的。这个框架允许采用(未修改的接受),适应(接受与修改)和临床建议的从头发展。使用这个框架,在S3进程之后,更新了基本证据,并将来自26个利益相关者组织的111名代表组成的代表性指南小组分为四个工作组。遵循正式的S3流程,所有临床建议均对其在英国的适用性进行了正式评估,并据此予以采纳.
结论:使用ADOLOPMENT协议,制定了英国版本的EFPS3级临床实践指南,用于预防和治疗种植体周围疾病。该指南提供了与包括公众在内的英国医疗保健界直接相关的基于证据和共识的临床建议。
结论:S3级指南结合了对正式证据的评估,建议的分级和综合与广泛的利益相关者的临床专业知识。国际S3级指南是为了在英国医疗保健系统中直接临床适用性而实施的,促进一致的,跨学科,公众参与的循证方法用于预防和治疗种植体周围疾病。
OBJECTIVE: to adapt the supranational European Federation of Periodontology (EFP) Prevention and Treatment of Peri-implant Diseases - The EFP S3 Level Clinical Practice Guideline for UK healthcare environment, taking into account a broad range of views from stakeholders and patients.
METHODS: This UK version, based on the supranational EFP guideline [1] published in the Journal of Clinical Periodontology, was developed using S3-level methodology, combining assessment of formal evidence from 13 systematic reviews with a moderated consensus process of a representative group of stakeholders, and accounts for health equality, environmental factors and clinical effectiveness. It encompasses 55 clinical recommendations for the Prevention and Treatment of Peri-implant Diseases, based on the classification for periodontal and peri‑implant diseases and conditions [2].
METHODS: The UK version was developed from the source guideline using a formal process called the GRADE ADOLOPMENT framework. This framework allows for adoption (unmodified acceptance), adaptation (acceptance with modifications) and the de novo development of clinical recommendations. Using this framework, following the S3-process, the underlying evidence was updated and a representative guideline group of 111 delegates from 26 stakeholder organisations was assembled into four working groups. Following the formal S3-process, all clinical recommendations were formally assessed for their applicability to the UK and adoloped accordingly.
CONCLUSIONS: Using the ADOLOPMENT protocol, a UK version of the EFP S3-level clinical practice guideline for the Prevention and Treatment of Peri-implant Diseases was developed. This guideline delivers evidence- and consensus-based clinical recommendations of direct relevance to the UK healthcare community including the public.
CONCLUSIONS: The S3-level-guidelines combine evaluation of formal evidence, grading of recommendations and synthesis with clinical expertise of a broad range of stakeholders. The international S3-level-guideline was implemented for direct clinical applicability in the UK healthcare system, facilitating a consistent, interdisciplinary, evidence-based approach with public involvement for the prevention and treatment of peri‑implant diseases.